Dual inhibition of EGFR and VEGFR was also tested in colon cancer [134], cutaneous squamous cell carcinoma [135], follicular thyroid cancer [136], oral cancer [137], orthotopic ovarian carcinoma [138], and prostate cancer [139,140]. This evidence concerns the gene EGFR and colonic neoplasm.